S&P 500 5,235.18 +1.02%EUR/USD 1.0840 +0.21%GBP/USD 1.2710 +0.14%USD/JPY 149.50 −0.18%BRENT $82.40 −0.81%BTC $67,800 −0.21%GOLD $2,341 +0.55%NASDAQ 16,420.55 +0.74%S&P 500 5,235.18 +1.02%EUR/USD 1.0840 +0.21%GBP/USD 1.2710 +0.14%USD/JPY 149.50 −0.18%BRENT $82.40 −0.81%BTC $67,800 −0.21%GOLD $2,341 +0.55%NASDAQ 16,420.55 +0.74%
A daily business newspaper · Founded in 2026

Money Talk

Finance and markets: business, quotes, gold, energy and releases.

Navigating Drug Marketing Submissions: A July Strategy Session

Biotech firms face an increasingly rigorous regulatory landscape where minor documentation gaps can trigger costly refuse-to-file outcomes. To address these hurdles, Xtalks is hosting a webinar on July 14, 2026, offering sponsors a roadmap for assessing submission readiness and streamlining the path to market approval for innovative therapies.

Navigating Drug Marketing Submissions: A July Strategy Session
Photo: Bio & News

Cathy Gatza, PhD, Vice President of Regulatory Strategy, and Elizabeth Narciso, Vice President of Regulatory Operations at Premier Research, will lead the session. The discussion focuses on identifying vulnerabilities in chemistry, manufacturing, and controls (CMC), as well as nonclinical and clinical data sets. By addressing these gaps during the pivotal trial phase, companies can mitigate risks and ensure their applications meet evolving global standards, including the latest eCTD requirements.

The live event, scheduled for 11am EDT, serves as a practical guide for sponsors aiming to synchronize their development programs with regional regulatory expectations. Beyond data preparation, the speakers will examine effective interaction strategies with agencies to accelerate the review process. Professionals seeking to refine their submission workflows can register through the Xtalks portal to gain insights into these critical operational strategies.

Share article
TelegramXFacebook

When reusing this material a link to Money Talk is required.

Comments (0)

Leave a comment

No comments yet. Be the first!